Thomas Capozza, MD

Senior Director, Scientific Affairs
Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals (Employment)

Poster(s):

• (P-543) The Incidence Rates of Hepatobiliary Diseases Among Non-alcoholic Steatohepatitis Patients Stratified by fibrosis-4 (FIB-4) Index for Liver Fibrosis

• (P-554) Identification of Patients with Nonalcoholic Steatohepatitis (NASH) in an Electronic Health Record (EHR) Database